Publications

  1. Cheungpasitporn W, Thongprayoon C, O'Corragain OA, Edmonds PJ, Ungprasert P, Kittanamongkolchai W, Erickson SB. The Risk of Kidney Cancer in Patients with Kidney Stones: A Systematic Review and Meta-analysis. QJM. 2014 Sep 09.
    View PubMed
  2. Erickson SB, Vrtiska TJ, Lieske JC. Effect of Cystone(R) on urinary composition and stone formation over a one year period. Phytomedicine. 2011 Jul 15; 18(10):863-7. Epub 2011 Mar 17.
    View PubMed
  3. Erickson SB, Vrtiska TJ, Canzanello VJ, Lieske JC. Cystone(R) for 1 year did not change urine chemistry or decrease stone burden in cystine stone formers. Urol Res. 2011 Jun; 39(3):197-203. Epub 2010 Dec 16.
    View PubMed
  4. Beck LH Jr, Fervenza FC, Beck DM, Bonegio RGB, Malik FA, Erickson SB, Cosio FG, Cattran DC, Salant DJ. Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy. J Am Soc Nephrol. 2011; 22(8):1543-50.
  5. Fervenza FC, Abraham RS, Erickson SB, Irazabal MV, Eirin A, Specks U, Nachman PH, Bergstralh EJ, Leung N, Cosio FG, Hogan MC, Dillon JJ, Hickson LJ, Li X, Cattran DC, Mayo Nephrology Collaborative Group. Rituximab therapy in idiopathic membranous nephropathy: a 2-year study. Clin J Am Soc Nephrol. 2010 Dec; 5(12):2188-98. Epub 2010 Aug 12.
    View PubMed
  6. Fervenza FC, Cosio FG, Erickson SB, Specks U, Herzenberg AM, Dillon JJ, Leung N, Cohen IM, Wochos DN, Bergstralh E, Hladunewich M, Cattran DC. Rituximab treatment of idiopathic membranous nephropathy. Kidney Int. 2008 Jan; 73(1):117-25. Epub 2007 Oct 17.
    View PubMed
  7. Fervenza FC, Fitzpatrick PM, Mertz J, Erickson SB, Liggett S, Popham S, Wochos DN, Synhavsky A, Hippler S, Larson TS, Bagniewski SM, Velosa JA, Mayo Nephrology Collaborative Committee. Acute rapamycin nephrotoxicity in native kidneys of patients with chronic glomerulopathies. Nephrol Dial Transplant. 2004 May; 19(5):1288-92. Epub 2004 Feb 19.
    View PubMed
  8. Erickson SB, Lieske JC. Medical management. Clinical Reviews in Bone & Mineral Metabolism. 2004; 2(3):237-51.
    View PubMed
  9. Ramakumar S, Patterson DE, LeRoy AJ, Bender CE, Erickson SB, Wilson DM, Segura JW. Prediction of stone composition from plain radiographs: a prospective study. J Endourol. 1999 Jul-Aug; 13(6):397-401.
    View PubMed
  10. Griffin MD, Bjornsson J, Erickson SB. Diffuse proliferative glomerulonephritis and acute renal failure associated with acute staphylococcal osteomyelitis. J Am Soc Nephrol. 1997 Oct; 8(10):1633-9.
    View PubMed
  11. Torres VE, Erickson SB, Smith LH, Wilson DM, Hattery RR, Segura JW. The association of nephrolithiasis and autosomal dominant polycystic kidney disease. Am J Kidney Dis. 1988 Apr; 11(4):318-25.
    View PubMed
  12. Erickson SB, Cooper K, Broadus AE, Smith LH, Werness PG, Binder HJ, Dobbins JW. Oxalate absorption and postprandial urine supersaturation in an experimental human model of absorptive hypercalciuria. Clin Sci (Lond) 1984 Jul; 67(1):131-8.
    View PubMed
  13. Erickson SB. When should the stone patient be evaluated? Limited evaluation of single stone formers. Med Clin North Am. 1984 Mar; 68(2):461-8.
    View PubMed
  14. Broadus AE, Erickson SB, Gertner JM, Cooper K, Dobbins JW. An experimental human model of 1, 25-(OH)2D-medicated hypercalcemia. J Clin Endocrinol Metab. 1984; 59:202-206.
    View PubMed
  15. Hosking DH, Erickson SB, Van den Berg CJ, Wilson DM, Smith LH. The stone clinic effect in patients with idiopathic calcium urolithiasis. J Urol. 1983 Dec; 130(6):1115-8.
    View PubMed
  16. Erickson SB. Clinical brief: hypercalciuria. Mayo Clin Proc. 1981 Sep; 56:579.
  17. Erickson SB. A rational approach to nephrotoxic drugs in the elderly. Geriatrics. 1980 Jul; 35(7):55-63.
    View PubMed
  18. Erickson SB, Kurtz SB, Donadio JV Jr, Holley KE, Wilson CB, Pineda AA. Use of combined plasmapheresis and immunosuppression in the treatment of Goodpasture's syndrome. Mayo Clin Proc. 1979 Nov; 54(11):714-20.
    View PubMed